JOHANNESBURG (Reuters) – The South African government is not planning to buy Merck’s COVID-19 treatment pill molnupiravir because an evaluation score from an advisory committee indicated it would not be cost-effective, senior health official Nicholas Crisp told Reuters.
The country’s health regulator SAHPRA said on Thursday that it had authorised use of molnupiravir.
(Reporting by Alexander Winning; Editing by Olivia Kumwenda-Mtambo)
